Sonoma Pharmaceuticals (SNOA) Projected to Announce Quarterly Earnings on Thursday

Sonoma Pharmaceuticals (NASDAQ:SNOA) is anticipated to issue its results before the market opens on Thursday, August 6th. Analysts expect Sonoma Pharmaceuticals to post earnings of ($0.30) per share and revenue of $4.99 million for the quarter.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last posted its earnings results on Tuesday, June 16th. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.09). The firm had revenue of $5.56 million for the quarter, compared to analysts’ expectations of $5.57 million. Sonoma Pharmaceuticals had a negative net margin of 16.26% and a negative return on equity of 43.95%.

Sonoma Pharmaceuticals Stock Down 3.5%

SNOA stock opened at $1.10 on Thursday. Sonoma Pharmaceuticals has a 52 week low of $0.85 and a 52 week high of $6.92. The firm has a 50 day moving average of $1.16 and a 200 day moving average of $1.98. The stock has a market capitalization of $5.27 million, a PE ratio of -0.58 and a beta of 1.27.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sonoma Pharmaceuticals in a research note on Friday, July 24th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Sonoma Pharmaceuticals

A hedge fund recently raised its position in Sonoma Pharmaceuticals stock. DRW Securities LLC grew its stake in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) by 257.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 60,977 shares of the company’s stock after acquiring an additional 43,907 shares during the quarter. DRW Securities LLC owned about 3.59% of Sonoma Pharmaceuticals worth $222,000 as of its most recent SEC filing. 1.95% of the stock is currently owned by hedge funds and other institutional investors.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.